Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [41] ACTIVATION OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IN PATIENTS WITH SYSTEMIC SCLEROSIS
    Del Papa, N.
    Filippini, P.
    De Cristofaro, R.
    Sambataro, D.
    Rovelli, F.
    Vitali, C.
    Locatelli, F.
    Rutella, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 831 - 831
  • [42] Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors
    Dolusic, Eduard
    Larrieu, Pierre
    Blanc, Sebastien
    Sapunaric, Frederic
    Pouyez, Jenny
    Moineaux, Laurence
    Colette, Delphine
    Stroobant, Vincent
    Pilotte, Luc
    Colau, Didier
    Ferain, Thierry
    Fraser, Graeme
    Galleni, Moreno
    Frere, Jean-Marie
    Masereel, Bernard
    Van den Eynde, Benoit
    Wouters, Johan
    Frederick, Raphael
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (07) : 3058 - 3065
  • [43] Indoleamine 2,3-Dioxygenase 1 (IDO1) Expression in Biliary Tract Cancers
    Bavi, Prashant
    Hedley, David
    Knox, Jennifer J.
    Serra, Stefano
    MODERN PATHOLOGY, 2017, 30 : 160A - 161A
  • [44] Indoleamine 2,3-dioxygenase 1 (IDO1) regulates immune evasion in lymphoma
    Park, Jihyun
    Yoo, Seung-Joo
    Hu, Qianni
    Fielder, Carly M.
    Yoon, Hyundong
    Hong, Junshik
    Kim, Byung-Su
    Koh, Youngil
    Kim, Tae Kon
    Yoon, Sung-Soo
    Yan, Chi
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Indoleamine 2,3-Dioxygenase 1 (IDO1) Expression in Biliary Tract Cancers
    Bavi, Prashant
    Hedley, David
    Knox, Jennifer J.
    Serra, Stefano
    LABORATORY INVESTIGATION, 2017, 97 : 160A - 161A
  • [46] Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Roehrig, Ute F.
    Majjigapu, Somi Reddy
    Vogel, Pierre
    Reynaud, Aline
    Pojer, Florence
    Dilek, Nahzli
    Reichenbach, Patrick
    Ascencao, Kelly
    Irving, Melita
    Coukos, George
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2022, 37 (01) : 1773 - 1811
  • [47] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
    Tang, Kai
    Wang, Bo
    Yu, Bin
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227
  • [48] Indoleamine-2,3-dioxygenase 1 (Ido1) deficiency in myeloidderived cells, not microglia, attenuates LPS-induced depressionlike behaviors
    McCusker, Robert H.
    Kaswan, Zoe A. MacDowell
    Chen, Emily Y.
    BRAIN BEHAVIOR AND IMMUNITY, 2022, 106 : 25 - 25
  • [49] Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors
    Panda, Subhankar
    Roy, Ashalata
    Deka, Suman Jyoti
    Trivedi, Vishal
    Manna, Debasis
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1167 - 1172
  • [50] Indoleamine-2,3-Dioxygenase 1 (IDO1) Mediates Gastric Metaplasia via the Induction of Caspase 1 and the Production of Bioactive IL-1β
    El-Zaatari, Mohamad
    Chang, Yu-Ming
    Zhang, Min
    Shreiner, Andrew
    Kao, John Y.
    GASTROENTEROLOGY, 2014, 146 (05) : S27 - S27